首页|万古霉素腹腔给药治疗腹膜透析相关性腹膜炎的血药浓度监测结果分析

万古霉素腹腔给药治疗腹膜透析相关性腹膜炎的血药浓度监测结果分析

扫码查看
目的:分析腹膜透析相关性腹膜炎(PDRP)万古霉素腹腔给药方案与血药浓度监测情况,探讨万古霉素血药浓度与临床结局的关系。方法:收集 2020 年 1 月至 2023 年 4 月海南省人民医院经万古霉素腹腔给药治疗且监测血药浓度的 40 例PDRP患者资料,分析万古霉素血药浓度的分布情况、各方案首次血药浓度水平、依据血药浓度调整给药方案的情况以及血药浓度与临床结局的关系。结果:(1)69 例次万古霉素血药浓度结果中,血药浓度主要分布于 10~15 mg/L(28 例次,占 40。58%),平均浓度为(15。54±5。25)mg/L;治疗期间,监测1 次、2 次和3 次及以上血药浓度的患者分别为20、15 和5 例,其中,依次有6、15 和5 例患者依据血药浓度调整了万古霉素给药方案。(2)以万古霉素 0。5 g,1 日 1 次、隔日 1 次和隔 2 日 1 次腹腔给药;1 日 1 次方案的首次血药浓度为(17。11±4。43)mg/L,隔日 1 次方案的首次血药浓度为(14。92±4。21)mg/L,隔 2 日 1 次方案的首次血药浓度为(11。27±2。66)mg/L,1 日 1 次方案与隔 2 日 1 次方案首次血药浓度的差异有统计学意义(P<0。01)。(3)以 15 mg/L为界分组,高浓度组与低浓度组患者有效率的差异无统计学意义(P>0。05);以 10 mg/L 为界分组,浓度<10 mg/L 组患者的有效率为25。00%(1/4),显著低于浓度≥10 mg/L组的 83。33%(30/36),差异有统计学意义(P<0。05)。结论:万古霉素腹腔给药的血药浓度存在着较大个体差异,建议优先选用 0。5 g、1 日 1 次方案或首剂给予更高的负荷剂量,血药浓度维持≥10 mg/L;对于多次给药及方案调整的患者,应动态监测血药浓度。
Analysis on Results of Blood Concentration Monitoring of Vancomycin by Intraperitoneal Administration in the Treatment of Peritoneal Dialysis-Related Peritonitis
OBJECTIVE:To analyze the dosage regimen and blood concentration monitoring of vancomycin by intraperitoneal administration for peritoneal dialysis-related peritonitis(PDRP)in Hainan General Hospital,and to probe into the correlation between blood concentration of vancomycin and clinical outcome.METHODS:Case data of 40 patients received vancomycin intraperitoneally with blood concentration monitoring in Hainan General Hospital from Jan.2020 to Apr.2023 were collected and analyzed in terms of the distribution of blood concentration of vancomycin,the first-time blood concentration levels of various regimens,adjustment of dosing regimens based on blood concentration,correlation between blood concentration and clinical outcome.RESULTS:(1)Among 69 cases of vancomycin blood concentration results,the blood concentration was mainly distributed in the range from 10 mg/L to 15 mg/L(28 cases,40.58%),with a mean concentration of(15.54±5.25)mg/L.During treatment,the numbers of patients who were monitored for once,twice and three or more times of blood concentration were respectively 20,15 and 5,of which successively 6,15 and 5 patients had adjusted vancomycin dosing regimen based on blood concentration.(2)And 0.5 g vancomycin was administered intraperitoneally qd,qod and q2d.The first blood concentration of the qd regimen was(17.11±4.43)mg/L,that of the qod regimen was(14.92±4.21)mg/L,and that of the q2d regimen was(11.27±2.66)mg/L,the difference in first blood concentrations between the qd regimen and the q2d regimen was statistically significant(P<0.01).(3)Using 15 mg/L as the boundary for grouping,the difference in the effective rates between high-concentration group and low-concentration group was not statistically significant(P>0.05);using 10 mg/L as the boundary for grouping,the effective rate of patients in the concentration<10 mg/L group was 25.00%(1/4),significantly lower than that 83.33%(30/36)in the concentration≥10 mg/L group,with statistically significant difference(P<0.05).CONCLUSIONS:There are large individual differences in the blood concentration of vancomycin by intraperitoneal administration,and it is recommended that the 0.5 g,qd regimen be preferred or a higher loading dose be given for the first dose,with the blood concentration maintained at≥10 mg/L.Blood concentration should be monitored dynamically in patients who have received multiple administrations and regimen adjustments.

Peritoneal dialysis-related peritonitisVancomycinTherapeutic drug monitoringBlood concentration

谢静、张莹、沈正泽

展开 >

海南省人民医院/海南医科大学附属海南医院药学部,海口 570311

海南省人民医院/海南医科大学附属海南医院肾内科,海口 570311

重庆医科大学附属永川医院药学部,重庆 402160

腹膜透析相关性腹膜炎 万古霉素 治疗药物监测 血药浓度

海南省卫生健康行业科研项目重庆市科卫联合医学科研项目

22A2000162022MSXM047

2024

中国医院用药评价与分析
中国医药生物技术协会,中国药房杂志社

中国医院用药评价与分析

CSTPCD
影响因子:1.142
ISSN:1672-2124
年,卷(期):2024.24(7)